Medtronic buys spinal cord stimulation therapy developer Stimgenics
Category: #health  By Mateen Dalal  Date: 2020-01-09
  • share
  • Twitter
  • Facebook
  • LinkedIn

Medtronic buys spinal cord stimulation therapy developer Stimgenics
  • DTM waveform will help improve the outcome for patients with chronic pain
     
  • The transaction will remain neutral to earnings per share for fiscal year 2020

Medtronic plc., a leading medical technology firm announced that it has bought Illinois-based company Stimgenics, LLC, that has developed a spinal cord stimulation (SCS) waveform broadly called Differential Target multiplexed (DTM) Spinal Cord Stimulation. The therapy is essentially delivered through the Medtronic Intellis platform and is known for its unique and new programming option that helps treat patients suffering from chronic pain.

Reportedly, the company will be presenting results covering three months of the randomized control trial (RCT) that evaluated DTM against conventional SCS at the North American Neuromodulation Society (NANS) 23rd Annual Meeting in January.

Dr. Ricardo Vallejo, the lead investigator and founder of Stimgenics, LLC as well as the director and co-founder of Illinois-based research at Millennium Pain Center, commented that research of Stimgenics has been rooted deeply within clinical science which started with animal work decades ago.

The company’s preclinical data had revealed that the modulation of glial cells and neurons are capable of returning glial cells back to their normal state and also modify their interactions with neurons that could help normalize the biological processes for breaking the pain cascade.

Vallejo added that Medtronic's acquisition can potentially improve the outcome for patients suffering from chronic pain significantly.  

Several medical society meetings have recognized the preclinical research on the neuronal-glial mechanism of action done by Stimgenics. The team has secured six awards over the span of two years for its research, out of which three of them were specific to the investigation of the DTM mechanism of action.

President for the Pain Therapies business, a part of the Restorative Therapies Group located at Medtronic, Marshall Stanton, M.D., stated that the company is dedicated to offering therapeutic options that are clinically-proven for millions of patients with chronic pain. The company believes that DTM therapy will be advancing the treatment for chronic pain backed by preclinical research and clinical evidence.

 

Source Credit- http://newsroom.medtronic.com/news-releases/news-release-details/medtronic-acquires-stimgenics-pioneer-dtmtm-novel-spinal-cord

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

Microsoft to fix an active security flaw in Internet Explorer
Microsoft to fix an active security flaw in Internet Explorer
By Mateen Dalal

Microsoft, the renowned American tech giant, reportedly verified the presence of a security flaw that is affecting Internet Explorer (IE) and is being used by hackers. The company also said it is working to find a fix for this bug, which would be rel...

Dermtech signs a commercial & medicare advantage coverage agreement
Dermtech signs a commercial & medicare advantage coverage agreement
By Mateen Dalal

DermTech Inc., a San Diego based biotechnology company that is involved in precision dermatology, has recently announced signing a contract with a regional health plan to develop its gene expression based PLA (Pigmented Lesion Assay) for prior detect...

CoImmune Inc. inks all-stock merger deal with Formula Pharmaceutical
CoImmune Inc. inks all-stock merger deal with Formula Pharmaceutical
By Mateen Dalal

The merger will bring two therapeutic immune-oncology platforms together Focus shall be placed over Phase 1 and Phase 2 trials of CAR-CIK and CMN-001 respectively U.S.-based bioscience firm CoImmune, Inc., announces partnership with Formula Phar...